Y-mabs files for EU approval for pediatric cancer drug
On Tuesday, Danish biotech firm Y-mabs submitted an application to get approval for the cancer drug omburtamab, according to the firm.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
US-Danish Biotech firm Y-mabs, which is listed on US Stock Exchange Nasdaq, has submitted a new application for marketing authorization for a cancer treatment. This was revealed after the close of trading on Tuesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA requires more data from Y-mabs
For subscribers
